Clinical Trial Update: A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating bevacizumab plus irinotecan in recurrent gliomas (glioblastoma and astrocytoma) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma
• Glioblastoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Clinical Research Center for Solid Tumor, Korea | Conditions: Glioblastoma, Astrocytoma | Phase 2 | Status: COMPLETED